期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

乳腺癌新辅助治疗疗效相关因素分析 被引量：4

Analysis on the factors related with the response of neoadjuvant therapy in primary breast cancer
原文传递
导出
摘要 目的对乳腺癌新辅助治疗疗效相关因素进行分析。方法选择2009年1月至2010年8月在北京大学第一医院乳腺疾病中心接受新辅助治疗的原发乳腺癌病人为研究对象,以蒽环类及紫杉类细胞毒药物为新辅助化疗基础方案,并对人类表皮生长因子受体2(HER2)阳性病人联合应用曲妥珠单抗。参照实体肿瘤疗效评价标准(RECIST1.1)及组织学分级系统(Miller and Payne grading system)对新辅助治疗疗效进行综合评价。结果共105例病人入组,动态增强MRI评价临床完全缓解(CR)12例(11.4%),部分缓解(PR)68例(64.8%),疾病稳定(SD)24例(22.9%),疾病进展(PD)1例(1.0%);组织分级系统评价:30例(28.6%)G5(病理完全缓解,pCR),35例(33.3%)G4,17例(16.2%)G3,12例(11.4%)G2,11例(10.5%)G1。单因素分析提示,肿瘤临床T分期和N分期较早,高组织学分级、Ki67、p53及HER2高表达与病理完全缓解率相关,且差异有统计学意义(P<0.01);而雌激素受体(ER)、孕激素受体(PR)及CK5/6在疗效评价中差异无统计学意义(P>0.05)。结论 T分期、N分期、组织学分级、HER2、Ki67、p53与新辅助治疗疗效具有相关性。 Objective To assess the effect of neoadjuvant therapy and to investigate the factors related with the response of neoadjuvant therapy in breast cancer patients. Methods We reviewed data of the primary breast cancer patients who had received neoadjuvant therapy with complete MRI data and who had received operation with histopathology evaluation in our center from January, 2009 to August, 2010. The neoadjuvant therapy regimens were based on anthraeyclines and taxanes, and trastuzumab was used in most of the HER2 positive patients. The response of neoadjuvant therapy was comprehensively evaluated based on RECISTI.1 and Miller-Payne grading system. Results Among the 105 patients, 12 （11.4% ）patients had CR, 68 （64.8%）patients had PR, 24 （22.9%）patients had SD and 1 （1.0%） patient had PD according to the MRI evaluation. While according to the Miller-Payne grading system, 30 （28.6%） patients had GS, 35 （33.3%） patients had G4,17 （16.2%）patients had G3, 12 （11.4%） patients had G2, 11 （ 10.5% ） patients had G1. The analysis suggests that the smaller tumor size, fewer positive lymph nodes, and higher histological grade were correlated with pCR statistically. Meanwhile the results of IHC suggested that strong express of HER2, Ki67 and p53 are related to pCR in a statistically significant way （P 〈 0.01）, while the express of ER, PR and CK5/6 had no correlation with pCR. Conclusion The effect of new adjuvant therapy can be predicted. The tumor size, lymph node status, histological grade and the IHC results of HER2, Ki67 and p53 were related to the pCR of new adjuvant therapy for primary breast cancer.
作者 程岩 徐玲 刘倩 刘荫华
机构地区 北京大学第一医院乳腺疾病中心 河北省优抚医院
出处 《中国实用外科杂志》 CSCD 北大核心 2012年第11期950-952,共3页 Chinese Journal of Practical Surgery
基金 首都医学发展基金项目(No:2009-1011) 北京市科技计划项目(No:D090507043409010)
关键词 乳腺癌 新辅助治疗 breast cancer new adjuvant therapy
分类号 R6 [医药卫生—外科学]
  • 相关文献

参考文献6

  • 1Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours:Revised RECIST guideline (version 1.1)[J]. Euro J Cancer, 2009, 45(2): 228-247.
  • 2Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival [J].Breast, 2003, 12(5): 320-327.
  • 3黄平,莫军扬,任占平.乳腺癌组织中MCM-5和Ki-67的表达及临床意义[J].中国实用外科杂志,2009,29(2):164-166. 被引量：7
  • 4徐玲,刘荫华,叶京明,赵建新,段学宁,张澜波,张虹,王韫宏.乳腺癌组织Ki67表达与蒽环类联合紫杉类新辅助化疗效果的相关性[J].中华外科杂志,2010,48(6):450-453. 被引量：25
  • 5Rohan TE, Li SQ, Hartwick R, el al. p53 alterations and protein accumulation in benign breast tissue and breast cantor risk: a cohort study [J]. Cancer Epidemiol Biomarkers Prey, 2006, 15 (7): 1316-1323.
  • 6Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 [J ]. Ann Oncol, 2011,22 (8):1736-1747.

二级参考文献16

  • 1Bailis JM,Forsburg SL.MCM protein :DNA damage ,mutagenesis and repair[J].Curr Opin in Genet Dev,2004,14( 1 ):17-21.
  • 2Snyder M,He W,Zhang JJ.The DNA replication factor MCM-5 is essential far Statl-mediated transcriptional activation [J]. Proc Natl Acad Sci USA,2005,102(41):14539-14544.
  • 3Guida T,Salvatore G,Faviana P,et al. Mitogenic effects of the up-regulation of minichromosome maintenance proteins in anaplastic thyroid carcinoma [J].J Clin Endocinol Metab,2005,90 (8): 4703-4709.
  • 4Sirieix PS, ODonovan M, Brown J, et el. Surface expression of minichromosome maintenance proteins provides a novel method for detecting patients at risk for developing adenoeareinoma in Barrett' s esophagus[J]. Clin Cancer Res, 2003, 9(7): 2560-2566.
  • 5Therasse P, Arbuck SG, Eisenhaner EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 2000, 92:205-216.
  • 6Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy : prognostic significance and survival. Breast, 2003, 12 : 320-327.
  • 7Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol, 2006, 24: 2019-2027.
  • 8Heller W, Mazhar D, Ward R, et al. Neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer. Oncol Rep, 2007, 17: 253-259.
  • 9Sehag CC, Heinrieh RL, Ganz PA. Karnofsky performance status revisited : reliability, validity, and guidelines. J Clin Oncol, 1984, 2 : 187-193.
  • 10Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol, 1998, 16: 2672-2685.

共引文献30

同被引文献53

  • 1Botteri E, Bagnardi V, Rotmensz N, et al. Analysis of localand regional recurrences in breast cancer after conserva- tive surgery [ J ]. Ann Oncol, 2010 (21 ) :723 - 728.
  • 2Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer:finding from national surgical adjuvant breast and bowel project[ J]. Clin Onco, 2010(3) :441 -452.
  • 3Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of radiotherapy and differences in the extent of surgery for early breast cancer on local recur- rence and 15 -year survival: an overview of the random- ized trials. Lancet, 2005 (9472) : 1687 - 1717.
  • 4Fisher B, Bryant J, Dignam JJ, et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpeetomy in women with invasive breast cancers of one centimeter or less[J]. J Clin Oneol, 2002(20) :4141-4149.
  • 5Jemal A, Bray F, Center MM, et al. Global cancer statistics [ J ]. CA Cance J Clin,2011,61 (2) :69-90.
  • 6Yerushalmi R, Woods R, Ravdin PM, et al. Ki67 in breast cancer: prognostic and predictive potential [ J ]. Lancet Oncol, 2010,11 (2) :174-183.
  • 7Gerdes J, Schwab U, Lemke H, et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation [ J ]. Int J Cancer, 1983, 31(1) :13-20.
  • 8Gerdes J,Lemke H,Baisch H,et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki67 [ J ]. J Immund, 1984, 133 ( 4 ) : 1710-1715.
  • 9MacCallum DE, Hall PA. The location of pKi67 in the outer dense fibrillary compartment of the nucleolus points to a role in ribosome biogenesis during the cell division cycle [ J ]. J Pathol, 2000,190 ( 5 ) :537-544.
  • 10Cheang MC, Chia SK, Voduc, D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer [ J]. J Natl Cancer Inst ,2009,101 (10) :736-750.

引证文献4

二级引证文献16

中国实用外科杂志
2012年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部